The European Medicines Agency (EMA) has given a positive recommendation for Rytelo ( imetelstat) for the treatment of adult ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

Anthony Olson was told he’d die without treatment and to ignore a negative biopsy. He’s one of many patients who may have ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves ...

We recently compiled a list of the 10 Biggest Losers of This Week. In this article, we are going to take a look at where ...